G1 Therapeutics, Inc.
G1T38 superior dosage regimes

Last updated:

Abstract:

A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.

Status:
Grant
Type:

Utility

Filling date:

8 Jul 2020

Issue date:

14 Jun 2022